• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coherus BioSciences, Inc. - Common Stock (NQ: CHRS )

    1.470 -0.020 (-1.34%)
    Streaming Delayed Price Updated: 1:59 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,237,715
    Open 1.460
    Bid (Size) 1.460 (14)
    Ask (Size) 1.470 (13)
    Prev. Close 1.490
    Today's Range 1.435 - 1.580
    52wk Range 0.6603 - 3.700
    Shares Outstanding 115,213,407
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -53.18%
    -53.18%
    1 Month
    +14.84%
    +14.84%
    3 Month
    +38.68%
    +38.68%
    6 Month
    -13.53%
    -13.53%
    1 Year
    -45.35%
    -45.35%

    More News

    Read More
    Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
    Via Benzinga
    Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
    Via Talk Markets
    Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    Why Coherus Biosciences Stock Tumbled on Thursday
    Via The Motley Fool
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.